CompanyEDITNasdaqCambridge, MA

Editas Medicine, Inc.

Editas Medicine develops in vivo CRISPR gene editing medicines.

SEC EDGAR ClinicalTrials.gov editasmedicine.com

10-QSep 2Latest SEC filing, period to Jun 30

Aug 5Latest story

August 2026

Editas reports Q2 2026 results, plans Australia CTN filing for EDIT-401

Aug 5Quarterly updateEditas Medicine, Inc.